Abstract: The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.

Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Abstract: The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of the glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.

Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Abstract: New GLP-1 derivatives, compositions thereof and their use in medicine.

Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Abstract: The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.

Abstract: The invention relates to cholecystokinin (CCK) derivatives of the general formula I: P-L-X1-X2-X3-Gly-Trp-X6-DMeAsp-X8-NH2, wherein P is Chem. 1: HOOC—(CH2)x—CO—*, wherein x is an integer in the range of 12-18; L is absent, or L comprises at least one linker element selected from Chem. 2: *—NH—CH(COOH)—(CH2)2—CO—*, Chem. 3: *—NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—* wherein k is an integer in the range of 1-11 and n is an integer in the range of 1-5, Chem. 4: *—NH—CH(CH2OH)—CO—*, Chem. 5: *—NH—CH2—CO—*, and/or Chem. 6: *—NH—CH[(CH2)4—NH2]—CO—*; X1 is absent, Asp, DAsp, bAsp, DbAsp, Glu, or DGlu; X2 is Phe(4-sulfomethyl) or sTyr; X3 is Nle, Leu, Ala, Ile, Lys, Arg, Pro, Met, Phe, Ser, His, or Val; X6 is Nle, Ile, Gln, Met, Met(O2), Leu, Val, Pro, Hpg, or Ala; X8 is Phe, MePhe, 1Nal, Me1Nal, 2Nal, Me2Nal, Trp, or MeTrp. The invention also relates to the corresponding CCK peptides, as well as to methods for preparing the peptides and the derivatives.

Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Abstract: New GLP-1 derivatives, compositions thereof and their use in medicine.

Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Abstract: The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.